Zurich, 23 September 2015 - UBS Wealth Management and MPM Capital collaborate to push development for cancer cures.

Jürg Zeltner, President of UBS Wealth Management: "This is a significant step on the journey to make impact investing a mainstream asset class. To do that, we need to ensure that investment returns stack up, while also producing a social good."

The market for cancer drugs is expected to grow faster than for any other disease, due to populations ageing in developed countries and an expanding middle class in emerging markets with better access to care. Oncology is the largest and fastest growing therapeutic area in terms of drug development activity, representing approximately 23% of total research spend.

UBS Wealth Management is a leader in offering sustainable investment opportunities. UBS Optimus Foundation supports the aims of the UBS and Society program, which seeks to create long-term, sustainable and measurable benefits for clients and communities.

MPM Capital is one of the most successful bioventure investment firms of the past decades. The firm has many years of experience in identifying breakthrough therapies, mostly from academia, and building successful new companies for their advancement. Over the last ten years, MPM has had numerous IPOs in healthcare.

UBS and MPM Capital will support academic research and better access to cancer care in the developing world.

Any investment opportunities arising out of this collaboration are likely to be restricted to specific qualifying investors only and will not be available for general distribution. This information pays no regard to specific investment objectives, financial or tax situations or particular needs of any recipient. UBS does not provide legal or tax advice.


UBS Group AG


Media contact
Switzerland: +41-44-234 85 00
www.ubs.com

About UBS

UBS draws on its over 150-year heritage to serve private, institutional and corporate clients worldwide, as well as retail clients in Switzerland. Its business strategy is centered on its pre-eminent global wealth management businesses and its leading universal bank in Switzerland, complemented by its Global Asset Management business and its Investment Bank, with a focus on capital efficiency and businesses that offer a superior structural growth and profitability outlook.

UBS is present in all major financial centers worldwide. It has offices in more than 50 countries, with about 35% of its employees working in the Americas, 36% in Switzerland, 17% in the rest of Europe, the Middle East and Africa and 12% in Asia Pacific. UBS Group AG employs about 60,000 people around the world. Its shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE).

About MPM Capital

MPM Capital is one of the most successful bioventure fund managers of the past decades. MPM has many years of experience in identifying breakthrough therapies, mostly from academia, and building successful new companies for their advancement. Over the last ten years, MPM had the largest number of IPOs in healthcare of any investment firm worldwide (31).

distributed by